申请人:SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT CO., LTD.
公开号:US20190177318A1
公开(公告)日:2019-06-13
Provided are a PDE4 inhibitor and a use thereof in the preparation of a medicament for treating PDE4 related diseases. Specifically disclosed are the compound as shown in formula (I) and a pharmaceutically acceptable salt thereof.
2-AMINO PYRIMIDINE COMPOUNDS AS POTENT HSP-90 INHIBITORS
申请人:Kung Pei-Pei
公开号:US20100041681A1
公开(公告)日:2010-02-18
The present invention is directed to compounds of formula (I),
or pharmaceutically acceptable salts thereof, their synthesis, and their use as HSP-90 inhibitors.
Cyclisierungen unter beteiligung von fluoridionen, 3. Mittell. [1,2] teilfluorierte 1.3- und 1.4-dioxane
作者:Guenter Siegemund、Warner Schwertfeger
DOI:10.1016/s0022-1139(00)81237-3
日期:1982.10
Cyclization of 2-(2-chloroethoxy)-perfluorocarboxylic acid halides 3 with alkalimetalfluoride gives 2.3-perfluoro- 1.4-dioxanes 6 with yields up to 84 %. This reaction is also used for the preparation of 4.5.6-perfluoro-1.3- dioxanes 12 starting from 3-chloromethoxyperfluorocarbonyl compounds 11. — The preparation of starting materials is described.
Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-Containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-Amino-4-{4-chloro-2-[2-(4-fluoro-1<i>H</i>-pyrazol-1-yl)ethoxy]-6-methylphenyl}-<i>N</i>-(2,2-difluoropropyl)-5,7-dihydro-6<i>H</i>-pyrrolo[3,4-<i>d</i>]pyrimidine-6-carboxamide
作者:Luke Zehnder、Michael Bennett、Jerry Meng、Buwen Huang、Sacha Ninkovic、Fen Wang、John Braganza、John Tatlock、Tanya Jewell、Joe Zhongxiang Zhou、Ben Burke、Jeff Wang、Karen Maegley、Pramod P. Mehta、Min-Jean Yin、Ketan S. Gajiwala、Michael J. Hickey、Shinji Yamazaki、Evan Smith、Ping Kang、Anand Sistla、Elena Dovalsantos、Michael R. Gehring、Robert Kania、Martin Wythes、Pei-Pei Kung
DOI:10.1021/jm200128m
日期:2011.5.12
A novel class of heatshockprotein90 (Hsp90) inhibitors was discovered by high-throughput screening and was subsequently optimized using a combination of structure-based design, parallel synthesis, and the application of medicinalchemistry principles. Through this process, the biochemical and cell-based potency of the original HTS lead were substantially improved along with the corresponding metabolic
2-Haloethylating agents for cancer chemotherapy. 2-Haloethyl sulfonates
作者:Y. Fulmer Shealy、Charles A. Krauth、Robert F. Struck、John A. Montgomery
DOI:10.1021/jm00362a016
日期:1983.8
Because certain (2-chloroethyl)triazenes and (2-haloethyl)nitrosoureas have high antineoplastic activity, 2-chloroethyl and 2-fluoroethyl sulfonates were prepared to try to develop additional types of 2-haloethylating agents. In this initial study, it was demonstrated that antineoplastic activity much superior to that of the prototype, 2-chloroethyl methanesulfonate, could be found among 2-chloroethyl
由于某些(2-氯乙基)三氮烯和(2-卤乙基)亚硝基脲具有很高的抗肿瘤活性,因此准备了2-氯乙基和2-氟乙基磺酸盐以尝试开发其他类型的2-卤乙基化剂。在这项初步研究中,证明了在2-氯乙基磺酸盐中可以发现抗肿瘤活性大大优于原型2-氯乙基甲烷磺酸盐。在各种2-氯乙基烷烃和芳烃磺酸盐中,几种取代的甲磺酸盐对小鼠的P388白血病表现出显着的活性。氯甲烷磺酸盐显示出高活性(T / C = 218%)。该测试中没有任何一种芳烃磺酸盐。